Paper Details

  1. Home
  2. Paper Details

Evaluation of rifaximin in management of hepatic encephalopathy.

Author: AhmedMostafa A, El-Deen SalemM Negm, El-DessoukyYasser M M, El-MolaKhaled, El-SayedAbeer M, El-TibyDiaa M, WahibAli A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared the efficacy of rifaximin and lactulose in treating hepatic encephalopathy, finding rifaximin to be a potentially better alternative.
Paper Details　
Original Abstract of the Article :
This study evaluated the efficacy of rifaximin versus lactulose in the treatment of hepatic encephalopathy (HE). The study population included 50 patients who were diagnosed to have signs of the first to third degree HE, according to the West Haven criteria and classified into two groups. GI: includ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.12816/0007871

データ提供：米国国立医学図書館（NLM）

Navigating the Brain Fog: Evaluating Rifaximin for Hepatic Encephalopathy

The desert of [hepatic encephalopathy (HE)] can be a confusing and disorienting place. This research sets out to explore a new route through this challenging terrain, examining the effectiveness of [rifaximin] compared to the established treatment of [lactulose] for [HE]. The researchers, like camel caravan leaders, carefully studied [50 patients with signs of the first to third degree HE] by dividing them into two groups: [25 patients treated with lactulose] and [25 patients treated with rifaximin]. This study found that [rifaximin significantly improved various subjective and measurable components of HE]. It's like finding a clear oasis in the midst of the desert's confusion, offering much-needed relief.

A New Oasis in the Desert of Hepatic Encephalopathy: Rifaximin Shows Promise

The research suggests that [rifaximin] may be a valuable new treatment for [HE], offering hope to patients who have been struggling with this condition. [Rifaximin] was found to be [better tolerated, associated with less frequent and shorter hospitalization in comparison to lactulose]. It's like discovering a new, more comfortable and convenient caravan route through the desert, making the journey less arduous.

Navigating the Desert of Hepatic Encephalopathy: Seeking Medical Guidance

[HE] is a complex condition that requires careful management. If you're facing this challenge, it's crucial to [consult with your doctor] to discuss the best treatment options for you. Remember, knowledge is your compass in this desert, guiding you towards optimal health.

Dr. Camel's Conclusion

This study sheds light on the potential of [rifaximin] as a promising treatment for [HE], offering a potentially safer and more effective alternative to [lactulose]. It's a reminder that [scientific research] is constantly evolving, leading us to new discoveries that can improve the lives of patients with [chronic liver disease].

Date :
  1. Date Completed 2015-03-16
  2. Date Revised 2019-11-13
Further Info :

Pubmed ID

25643509

DOI: Digital Object Identifier

10.12816/0007871

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.